Ocelot Bio Employee Directory
Biotechnology ResearchCalifornia, United States2-10 Employees
Ocelot Bio is a clinical-stage biotechnology company focused on developing therapies for complications of end-stage liver disease. Its lead candidate, OCE-205, is a peptide designed to address portal hypertension-related complications, including hepatorenal syndrome with acute kidney injury and ascites. The company has initiated a Phase 2 study of OCE-205 in HRS-AKI, and the FDA has granted Orphan Drug Designation for this indication. Based in San Diego, California, it operates within the biotechnology research sector, focusing on therapies for ESLD-related complications. With a small team, Ocelot Bio works in a specialized area of liver disease therapeutics. In 2023, the company appointed Lise Kjems as chief medical officer to lead its clinical development.